检索

期
标题
作者
卷 21, 编号 3 (2019)
Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
Reutova E., Laktionov K., Iudin D., Neliubina L., Gorokhova G., Egorova A.
卷 20, 编号 3 (2018)
The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer
Karabina E., Lubchenko L., Garunov A.
PDF
(Rus)
卷 20, 编号 2 (2018)
New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors
Laktionov K., Reutova E., Nelyubina L., Pitkevich M., Okruzhnova M., Ardzinba M., Yudin D., Demidova I., Zaretsky A.
PDF
(Rus)
卷 19, 编号 1 (2017)
The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
Ryazhenov V.
PDF
(Rus)
卷 24, 编号 1 (2022)
Osimertinib and routine practice: the experience of the drug application in different clinical situations in case of metastatic non-small cell lung cancer with an EGFR mutation. Case report
Orlov S., Baldin P., Diuzeva N., Krechetova A., Mordovskiy A., Moskovchenko A., Musaeva N., Romanchuk O.
PDF
(Rus)
卷 18, 编号 3 (2016)
Clinico-economic evaluation of different treatment strategies in patients with non-small cell lung cancer and mutations in the EGFR gene
Ryazhenov V., Gorokhova S.
PDF
(Rus)
卷 24, 编号 3 (2022)
The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
Nasretdinov A., Menshikov K., Sultanbaev A., Musin S., Sultanbaeva N., Men'shikova I.
PDF
(Rus)
卷 18, 编号 4 (2016)
Therapy for patients with non-small cell lung cancer in the Russian Federation: EPICLIN-Lung study
Tyulyandin S., Imyanitov E., Moiseyenko V., Ponomarenko D., Gurina L., Koroleva I., Karaseva V.
卷 23, 编号 1 (2021)
Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
Bogdanov A., Moiseenko F., Egorenkov V., Bogdanov A., Volkov N., Fedyanin M.
PDF
(Rus)
卷 16, 编号 3 (2014)
Russian multicenter retrospective study: preliminary data concerning clinical and molecular genetic characteristics in long-term responders to erlotinib
Smolin A., Gorbacheva A.
卷 22, 编号 3 (2020)
Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience
Ognerubov N., Sychev V., Kozlova N., Chang V.
PDF
(Rus)
卷 15, 编号 3 (2013)
Gefitinib – terapiya vybora 1-y linii nemelkokletochnogo raka legkogo u bol'nykh s nalichiem mutatsiy v gene EGFR
Bolotina L.
卷 15, 编号 4 (2013)
The ways of erlotinib resistance overcoming in treatment of patients with eGFr mutated nsClC
Orlov S.
1 - 13 的 13 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##